Clinical Trials in Michigan

Showing 1041-1060 of 16,154 trials

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

NCT05500807

Von Willebrand Disease (VWD) is the most common inherited bleeding disorder affecting up to 0.1% of the population, is usually characterized by mucocutaneous bleeding, HMB, surgical bleeding or other hemostatic challenges. Severe bleeding events require VWF concentrates administered solely through intravenous access. Emicizumab (Hemlibra) is a monoclonal bispecific antibody developed to bind activated FIX and FX and mimic FVIII cofactor functionality. Hemlibra is administered via subcutaneous injection rather than intravenous infusion. The hypothesis of this study is that Emicizumab is safe and efficacious for prophylaxis in severe VWD and concomitant VWD/hemophilia patients.

Von Willebrand Disease, Type 3Concomitant VWD and Hemophilia

Bleeding and Clotting Disorders Institute Peoria, Illinois40 participantsStarted Nov 2022

Orange, California, United States • Redwood City, California, United States • Coral Gables, Florida, United States +9 more locations

Active Not RecruitingPhase 353 miles

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

NCT06668064

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

EyePoint Pharmaceuticals, Inc.400 participantsStarted Oct 2024

Phoenix, Arizona, United States • Springdale, Arkansas, United States • Bakersfield, California, United States +76 more locations

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

Find Trials by Condition in Michigan

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Lung Ultrasound for Guiding Antibiotic Use in Pediatric Pneumonia

Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection

Post Market Evaluation of Clinical Safety and Performance of the Fitbone Transport and Lengthening System

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus

A Study of LY3200882 in Participants With Solid Tumors

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome